News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProFibrix Passes Halfway Mark of Patient Enrolment in Pivotal Phase 3 With Fibrocaps™ and Successfully Concludes Safety Review Assessment



11/8/2012 10:21:43 AM

LEIDEN, The Netherlands & SEATTLE--(BUSINESS WIRE)--ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced that the company has enrolled already more than half of the patients in its pivotal Phase III clinical trial with Fibrocaps (FINISH-3). In addition, it successfully concluded a meeting of the Data Monitoring Committee (DMC), an independent expert panel overseeing patient safety and treatment efficacy.

Read at BioSpace.com


comments powered by Disqus
ProFibrix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES